Skip to content

Engineered Koji Track

1. Gout weakness

Gout exposes several potentially engineerable weaknesses: intestinal urate can be targeted before reabsorption, and inflammatory amplification can be attacked at multiple points. The system-level rationale is documented in gut-lumen sink, NLRP3 exploit map, and gout kill-chain delivery routes.

2. Exploit hypothesis

Mechanistic extrapolation: an A. oryzae production system may provide active gout-relevant payloads in a useful oral or food-derived format if expression, physiological operating conditions, product stability, dose consistency, and safety gates are met.

This hypothesis does not require one strain, one format, home production, or a particular payload stack.

3. Proposed engineering

The track evaluates A. oryzae as a production chassis for uricase and selected immunomodulatory payloads. Construct architectures, candidate formats, and multi-cassette options are detailed in engineered-koji-protocol.md and koji-endgame-strain.md. Those designs are candidates within this track, not project requirements.

4. Evidence by level

  • Clinical Trial: Oral urate-degradation evidence informs the broader gut-sink premise; it does not validate engineered koji. See gut-lumen sink.
  • Animal Model: Relevant urate and inflammation findings are catalogued in the linked mechanism pages; no animal result establishes the complete engineered-koji product.
  • In Vitro: Chassis engineering, enzyme expression, protease stability, and assay evidence are maintained in engineered-koji-protocol.md, uricase, and the validation protocols.
  • Computational: Current computational priors are indexed in computational-experiments.md and require current COMP receipts before they can support synthesis.
  • Mechanistic Extrapolation: Combining payload, chassis, format, and gout endpoint remains an extrapolation until the linked gates are executed.

5. Key assumptions

  • A selected payload can be produced with the required activity and localization.
  • Activity survives the intended manufacturing, storage, and delivery format.
  • The payload operates under physiologically relevant substrate, oxygen, pH, residence-time, and protease conditions.
  • The achieved exposure is sufficient to change a gout-relevant endpoint.
  • Coproducts, organism state, contamination controls, and repeat exposure are acceptable for the intended use.

6. Failure modes and safety constraints

Payload misfolding, proteolysis, secretion failure, cassette interference, genetic instability, batch variation, contamination, GI inactivation, peroxide burden, allergenicity, and regulatory mismatch can each stop or redirect a specific configuration. The current threat model is in cross-validation.md.

7. Cheapest discriminating experiment

Start with the smallest payload–chassis assay that measures identity, active yield, and stability under the intended format. Do not build the full stack before single-payload and physiological operating-regime gates pass. Current protocols and ordering are maintained in validation-experiments.md.

8. Pass / revise / kill criteria

  • Pass: a configuration meets its predefined identity, activity, operating-regime, and safety gates; advance that configuration.
  • Revise: the gout weakness remains exploitable but the payload, topology, strain architecture, format, or manufacturing model must change.
  • Kill: no tested configuration can reach the required operating regime without unacceptable burden or safety risk, or a shared upstream experiment invalidates the targeted mechanism.

9. Status and next move

Active Phase 0 track. Resolve the current single-payload, physiological-regime, and safety gates before treating a multi-payload configuration as a product plan.

10. What remains true if this track fails

The gout exploit map, gut-sink evidence, payload data, assay methods, and non-koji tracks remain. A failed koji configuration can still identify a useful payload, operating constraint, delivery requirement, or better chassis.